AKER
NASDAQAkers Biosciences Inc.
Akers Biosciences Inc. (AKER) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. There were no new wire items for AKER in the last 30 days. The most recent was published Apr 28, 2021.
Latest news
25 items- SECSEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)S-3/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
- INSIDERSEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4 filed by EAGLE CRAIG4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 3 filed by EAGLE CRAIG3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- SECAkers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
- INSIDERSEC Form 4 filed by Kaplin Adam4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 3 filed by Kaplin Adam3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4 filed by Uzonwanne Jude4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 3 filed by Uzonwanne Jude3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 3 filed by Chapman Christopher C JR3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4 filed by Rivard Paul4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 3 filed by Rivard Paul3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4: SCHROEDER ROBERT C exercised 43,930 units of Common Stock at a strike of $0.00 and disposed of $72,588 worth of Common Stock (14,694 units at $4.94) (withholding obligation)4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4: Silverman Joshua exercised 109,500 units of Common Stock at a strike of $0.00 and disposed of $189,326 worth of Common Stock (38,325 units at $4.94), increasing direct ownership by 2,636% to 71,175 units (withholding obligation)4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- INSIDERSEC Form 4: White Billy Joe exercised 109,500 units of Common Stock at a strike of $0.00 and disposed of $189,326 worth of Common Stock (38,325 units at $4.94), increasing direct ownership by 2,636% to 71,175 units (tax liability)4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
- SECAkers Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Akers Biosciences, Inc. (0001321834) (Filer)
- PRAkers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of MergerShares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol "MYMD" Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1 Recently announced plans to initiate Phase 2 trial Akers Biosciences, Inc. ("Akers") (NASDAQ:AKER) and MyMD Pharmaceuticals, Inc. ("MYMD") today announced that at Akers' special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents fr
- SECSEC Form 425 filed by Akers Biosciences Inc.425 - Akers Biosciences, Inc. (0001321834) (Subject)
- PRAkers' Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression TrialAkers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. In a finding published in JAMA Network Open on 3/12/21, it was found that 52% of individuals who had COVID-19 had an associa
- SECSEC Form 425 filed by Akers Biosciences Inc.425 - Akers Biosciences, Inc. (0001321834) (Subject)
- PRAkers' Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory BoardChaired by Katharine Whartenby, Ph.D., members include experts in molecular medicine, aging, pathology and oncology Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. "Each member of our Scientific Adviso
- SECSEC Form EFFECT filed by Akers Biosciences Inc.EFFECT - Akers Biosciences, Inc. (0001321834) (Filer)
- SECSEC Form 424B3 filed by Akers Biosciences Inc.424B3 - Akers Biosciences, Inc. (0001321834) (Filer)
AKER FAQ
6 questionsWhat is the latest news on AKER?
Quantisnow has not tracked any new filings, ratings or press releases for AKER in the last 30 days. The most recent wire item was published on April 28, 2021.Where does AKER stock trade?
Akers Biosciences Inc. (AKER) is listed on NASDAQ.What sector and industry is AKER in?
Akers Biosciences Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Akers Biosciences Inc. go public?
Akers Biosciences Inc. (AKER) completed its IPO in 2014.What companies are similar to AKER?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), NEOG (Neogen Corporation), CLDX (Celldex Therapeutics Inc.). Compare AKER side-by-side with any of them on Quantisnow.How can I track AKER on Quantisnow?
Quantisnow aggregates Akers Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKER to receive live email and push alerts on every new disclosure.